Advertisement covers IAS 2013

Normal Life Expectancy Seen for North Americans With HIV

August 28, 2013

People living with HIV in North America who receive antiretroviral therapy have improving -- near normal, in fact -- life expectancy, according to new data presented at IAS 2013.

Investigators from the NA-ACCORD presented the results of their analysis of life expectancy among large cohorts in North America. The groups looked at 22,937 subjects over age 20 who were prescribed ART between 2000 and 2007. More than 82,000 patient-years of data and 1,600 deaths were included. The results showed that life expectancy at age 20 had increased from an additional 36 years in 2000-2002 to an additional 51 years in 2006-2007.

Life expectancy was lower among some demographic groups: individuals with a history of injection drug use, non-whites and individuals with a baseline CD4+ cell count less than 350 cells/mm3.

Which other studies presented at IAS 2013 will have lasting impact long after memories of the conference itself have faded? Read more of Dr. Llibre and Dr. Young's top picks.

Copyright © 2013 Remedy Health Media, LLC. All rights reserved.

This article was provided by TheBodyPRO. It is a part of the publication The 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.